Overview
This study aims to evaluate the additive effect of Amantadine to Pregabaline in the development of post-thoracotomy pain syndrome.
Description
Lung cancer is still the most common cause of cancer-related deaths, and lung resection surgeries could be the primary therapeutic option. Hence, the number of thoracotomy procedures is progressively increasing, as well as the development of post-thoracotomy pain syndrome (PTPS).
Pregabalin is one of the drugs that can reduce the excitability of the dorsal horn neurons. It is a γ-aminobutyric acid analogue that binds to α2-δ subunits of the voltage-gated calcium channels in the central nervous system.
Amantadine (1-aminoadamantane) is NMDA receptor antagonists. NMDA receptors were found to have role in the development of central sensitization, acute opioid tolerance, and opioid induced hyperalgesia.
Eligibility
Inclusion Criteria:
- Age (18-65) years.
- Both sexes.
- American Society of Anesthesiologists (ASA) Physical status II, III.
- Body mass index (BMI): (20-40) kg/m2.
- Cancer patients undergoing posterolateral thoracotomy incision for cancer lung, mesothelioma or other lung resection procedures.
Exclusion Criteria:
- Patients with known sensitivity or contraindication to drug used in the study.
- History of psychological disorders and/or chronic pain and drug abuse patients.
- Previous administration of antidepressants, anticonvulsants, or opioids before surgery.
- Patient refusal.
- Severe respiratory or cardiac disorders.
- Advanced liver or kidney disease.